Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Clinical Research Ventures is a global venture capital firm established to support companies in funding their clinical trials for pharmaceuticals, diagnostics, and medical technologies. Founded with a clear mission, the firm does not engage in purely pre-clinical investments. It operates from offices in Boston and Europe, allowing it to invest in companies worldwide.
The firm has a structured approach to investment, focusing on companies that are entering Phase I or II clinical trials. With an annual capacity of up to $50 million for trial costs, Clinical Research Ventures aims to enhance control for biotech and medtech companies while minimizing dilution. The firm has a portfolio of four notable companies, reflecting its commitment to the life sciences sector.
Clinical Research Ventures exclusively invests in companies conducting clinical trials within the life sciences sector. The firm partners with clinical research organizations to facilitate rapid start-up, enrollment, and successful trial completion for its portfolio companies. This partnership model is designed to expedite the clinical trial process, which is critical for the development of pharmaceuticals and medical technologies.
The investment strategy encompasses a range of stages from seed to growth equity, targeting companies that are actively engaged in clinical trials. The firm’s focus on funding trial costs allows it to support innovative solutions in pharmaceuticals, diagnostics, and medical technologies, ensuring that its portfolio companies can achieve their clinical objectives efficiently.
Clinical Research Ventures has a focused portfolio that includes four notable companies:
Nuno Arantes-Oliveira: Based in Lisbon, Nuno brings extensive experience in life sciences investments and has a strong background in clinical trial management.
Jean Frederic Sauniere: Located in Côte d’Azur, Jean has a deep understanding of the European biotech landscape and has been involved in numerous successful funding rounds.
Stan Kugell: Operating from Boston, Stan has a wealth of experience in venture capital and has led several notable investments in the healthcare sector.
To pitch Clinical Research Ventures, founders should reach out via email at contactus@cr-ventures.com. It is essential to include a detailed overview of the clinical trial objectives, the technology being developed, and any preliminary data supporting the trial.
As of October 2023, Clinical Research Ventures continues to actively support life sciences companies by funding clinical trials. The firm has not reported any recent exits or new fund announcements, but its ongoing commitment to facilitating successful trial completion remains a key focus.
What are the investment criteria for Clinical Research Ventures?
The firm invests exclusively in companies conducting clinical trials in the life sciences sector, focusing on those entering Phase I or II trials.
How can companies apply for investment?
Interested companies can apply for investment through the firm's website or by contacting them via email at contactus@cr-ventures.com.
What makes Clinical Research Ventures different from other investors?
Clinical Research Ventures specializes in funding clinical trials, providing up to $50 million annually to support trial costs, which enhances control and reduces dilution for portfolio companies.
What is the geographic scope of your investments?
The firm invests globally, with offices in Boston and Europe, allowing for a wide-reaching impact in the life sciences sector.
What type of post-investment involvement does Clinical Research Ventures have?
The firm partners with clinical research organizations to facilitate rapid start-up and successful trial completion, actively supporting its portfolio companies throughout the clinical trial process.
What is the typical check size for investments?
Clinical Research Ventures provides funding that can reach up to $50 million annually for trial costs, depending on the needs of the portfolio company.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.